基石藥業-B(02616.HK)已就投資事項聘請會計師獨立調查
基石藥業-B(02616.HK)公布,根據核數師的要求,審計委員會現已聘請一家「四大」會計師事務所(核數師除外)擔任法證會計專家,對有關2.27億元投資事項進行獨立調查。根據公司提供的進一步信息及調查結果,核數師可能要求額外資料及進行額外工作。
鑑於調查需時完成,落實公司去年度業績及完成審核可能比指定時限需要更長的時間。
公司上周公布,於截至去年12月底止年度的審核過程中,發現用約為2.27億元的資金於去年7月透過認購CMB International Global Products Limited發行的基金掛鉤票據用於投資一家於開曼群島註冊的獨立投資組合公司。公司正與核數師協力提供其他有關投資事項的包括有效性及可收回性相關的資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.